Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near
Cullinan Therapeutics executives have identified 2026 as a "defining year" due to anticipated catalysts from their T-cell engager programs, CLN-978 and CLN-049, and updates on their partnered EGFR exon 20 inhibitor, zipalertinib. The company reported over $430 million in cash, providing runway into 2029, and is pushing for first-in-class or best-in-class therapies in oncology and autoimmune diseases. Key developments include promising early AML activity for CLN‑049, advancing CLN‑978 for autoimmune diseases, and Taiho's near-complete rolling NDA submission for zipalertinib.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, at 10:00 a.m. ET. The clinical-stage biopharmaceutical company focuses on developing therapies for autoimmune diseases and cancer. A webcast of their discussion will be available on the company's investor relations website.
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum
Cullinan Therapeutics (NASDAQ: CGEM) anticipates a catalyst-rich 2026, driven by key advancements in its CLN-978 and CLN-049 programs. The company expects Q2 data for CLN-978, a T-cell engager for lupus and rheumatoid arthritis, focusing on B-cell depletion and safety. Additionally, CLN-049 for AML received FDA Fast Track designation, with plans for dose expansion and a Phase II study targeting 2027, supported by a strong cash position of over $430 million into 2029.
Precision Trading with Cullinan Oncology Inc. (CGEM) Risk Zones
This article provides an analysis of Cullinan Oncology Inc. (CGEM) stock with a focus on risk zones and trading strategies. It highlights a weak near-term sentiment but potential long-term strength, offering institutional trading strategies for different risk profiles. The analysis includes multi-timeframe signal analysis and AI-generated signals for real-time insights for investors.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30.00 price target, predicting a significant upside. The firm sees the current stock price as an attractive entry point, anticipating important Phase 1 data catalysts for the company's T-cell engagers in autoimmune diseases and AML throughout 2024. Cullinan's CLN-978 is highlighted as a key value driver, with upcoming data readouts in various autoimmune conditions, and another drug, CLN-049, has received Fast Track designation from the FDA for AML.
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Exploring a Promising 148.86% Upside in Biotech
Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company, is generating significant investor interest due to an estimated 148.86% potential upside, according to recent analyst ratings. Despite currently reporting losses and negative free cash flow characteristic of a developmental biotech, the company's strong pipeline, strategic collaborations, and positive analyst sentiment point towards a high-risk, high-reward investment opportunity in innovative therapies for autoimmune diseases and cancer. Technical indicators also suggest the stock is in oversold territory, which could appeal to long-term investors.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a potential 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data catalysts for the company's T-cell engagers in autoimmune diseases and AML in 2024. Cullinan's strong recent performance, with a 56% price return over the last six months, and the identification of CLN-978 as a primary value driver underpin this positive outlook.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com
Guggenheim has initiated coverage on Cullinan Oncology (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a "good entry point" ahead of anticipated Phase 1 data catalysts for its T-cell engagers. The firm highlights CLN-978 as a primary value driver, expecting data from dose escalations in autoimmune diseases later in 2024. Despite competitive risks, the analyst's outlook is supported by CGEM's recent strong performance and upcoming clinical milestones.
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, predicting a 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data releases for T-cell engagers in autoimmune diseases and AML throughout 2024, with CLN-978 identified as a key value driver. This positive outlook is supported by recent strong performance and other promising clinical developments for the company's therapeutic candidates.
Technical Reactions to CGEM Trends in Macro Strategies
This article provides a technical analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting conflicting market sentiment and elevated downside risk. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests choppy market conditions for CGEM based on current signals.
Insider Sell: Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc (CGEM)
Jennifer Michaelson, Chief Scientific Officer of Cullinan Oncology (a branch of Cullinan Therapeutics Inc), sold 4,000 shares of CGEM on January 22, 2026. This transaction leaves her with 128,635 shares in the company. Over the past year, Michaelson has sold a total of 15,142 shares, contributing to a total of 11 insider sells against 3 insider buys for Cullinan Therapeutics Inc during the same period.
Trading the Move, Not the Narrative: (CGEM) Edition
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting its current strong sentiment and potential for a breakout. It provides institutional trading strategies for various risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests elevated downside risk due to a lack of additional long-term support signals.
(CGEM) Volatility Zones as Tactical Triggers
This article provides an AI-driven analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), detailing volatility zones and tactical triggers for trading. It outlines institutional trading strategies including long, breakout, and short positions, complete with entry zones, targets, and stop losses. The analysis also covers multi-timeframe signal strengths, support, and resistance levels.
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) announced its 2026 clinical development plans, featuring multiple data readouts for its autoimmune program CLN-978 and advancements in its oncology portfolio. The company holds a strong cash position of $439 million, projecting a runway into 2029, despite a notable cash burn. Analysts currently consider the stock undervalued, highlighting key financial metrics for potential investors.
Cullinan Therapeutics plans data readouts for key autoimmune programs
Cullinan Therapeutics announced its 2026 clinical development plans, including upcoming data readouts for autoimmune and oncology programs, and reported a preliminary year-end cash position of $439 million. The company expects to release data for its autoimmune drug CLN-978 across three indications throughout 2026 and plans to advance its oncology drug CLN-049 for AML. Despite a strong stock performance and a solid cash position, InvestingPro notes that Cullinan is quickly burning through cash.
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Cullinan Therapeutics has provided a corporate update and outlined its anticipated milestones for 2026, focusing on its CLN-978, CLN-049, and zipalertinib programs. The company plans significant data readouts for autoimmune indications for CLN-978, aims to complete dose expansion for CLN-049 and initiate a frontline AML combination study, and expects the zipalertinib NDA submission to be completed with full enrollment in its frontline study. Cullinan also reported preliminary cash and investments of $439.0 million as of December 31, 2025, providing a runway into 2029.
Cullinan Oncology stock hits 52-week low at $9.49
Cullinan Oncology (CGEM) stock hit a 52-week low of $9.49 during intraday Monday trading, with 372,217 shares exchanging hands. Despite this, the stock maintains a market cap of $443.08 million.
How (CGEM) Movements Inform Risk Allocation Models
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to inform risk allocation. It highlights a weak sentiment across all horizons supporting a short bias and details three distinct trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data
TD Cowen has reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ:CGEM) after the company presented promising CLN-049 acute myeloid leukemia (AML) data at the American Society of Hematology (ASH) conference. Despite a recent stock dip, management highlighted the treatment's all-comer efficacy, favorable safety profile, and potential for an accelerated path to market. Analysts maintain a positive outlook, citing expected de-risking catalysts in 2026 and strong company liquidity.
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data
TD Cowen reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ:CGEM) after the company presented promising CLN-049 acute myeloid leukemia (AML) data at the American Society of Hematology (ASH) conference. Despite an 18% stock drop over the past week, management highlighted the treatment's all-comer efficacy, favorable safety profile, and potential for streamlined clinical development. Analysts anticipate multiple de-risking catalysts in 2026 for Cullinan's T-cell engager pipeline, reinforcing the Buy recommendation, with price targets ranging from $22 to $38.
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data
TD Cowen has reiterated a Buy rating on Cullinan Oncology (NASDAQ:CGEM) following its presentation of CLN-049 acute myeloid leukemia (AML) data at the ASH conference, despite an 18% stock drop. Management emphasized the treatment's "all-comer efficacy" and favorable safety profile, and TD Cowen anticipates multiple de-risking catalysts in 2026 for Cullinan's T-cell engager pipeline. This aligns with a broader analyst consensus and promising clinical data that led to a Fast Track designation for CLN-049 and increased price targets.
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates
Cullinan Therapeutics (CGEM) stock surged after announcing promising Phase 1 data for CLN-049 in Acute Myeloid Leukemia (AML), leading Clear Street to raise its price target to $33. The company also reported a Q3 2025 net loss of $50.6 million but maintains a strong cash position of $475.5 million, providing a financial runway into 2029. Cullinan Therapeutics has strategically narrowed its pipeline to focus on high-potential therapies by discontinuing certain programs to extend its cash runway and concentrate investments.
H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24
H.C. Wainwright has reiterated its Buy rating and $24 price target for Cullinan Oncology (NASDAQ:CGEM) following updated positive data from its Phase 2b REZILIENT1 trial for zipalertinib in NSCLC patients. The stock is currently trading near its 52-week low but is considered undervalued by InvestingPro analysis based on its Fair Value metrics. This comes amidst other recent positive developments, including continued support from analysts despite competing drug approvals.
Cullinan Oncology stock soars after promising AML treatment results
Cullinan Therapeutics' stock surged 16% after reporting promising clinical data for its leukemia treatment candidate, CLN-049, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome. The Phase 1 study showed a 31% complete response rate at the highest dose, with efficacy in difficult-to-treat patients and a favorable safety profile. The FDA also granted Fast Track designation to CLN-049.
Trading Systems Reacting to (CGEM) Volatility
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) volatility, identifying near-term weak sentiment but mid-term strength within a broader long-term weak bias. It details AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis also provides multi-timeframe signal analysis with support and resistance levels for various horizons.
Cullinan Therapeutics (Nasdaq: CGEM) granted FDA Fast Track for CLN-049 in R/R AML
Cullinan Therapeutics has received FDA Fast Track designation for CLN-049, a FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (R/R AML). This designation aims to accelerate development and regulatory review for CLN-049, which has shown promising efficacy, including complete responses, and favorable safety in Phase 1 trials. The company plans to present Phase 1 data at the 67th ASH Annual Meeting on December 8, 2025.
Cullinan Therapeutics Receives FDA Fast Track Designation
Cullinan Therapeutics has received FDA Fast Track designation for its novel FLT3xCD3 T cell engager, CLN-049, for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). This designation highlights the urgent need for new therapies in AML and the promising efficacy data from CLN-049's Phase 1 study, which will be further presented at the upcoming American Society of Hematology Annual Meeting. The company aims to accelerate the development and regulatory review of CLN-049 to address the significant unmet medical need for more effective treatments in this broad patient population.
Cullinan Therapeutics Receives FDA Fast Track Designation
Cullinan Therapeutics has received FDA Fast Track designation for CLN-049, a novel FLT3xCD3 T cell engager, for treating relapsed/refractory acute myeloid leukemia (AML). This designation highlights the urgent need for new AML treatments and CLN-049's potential, as evidenced by promising efficacy and safety data from its Phase 1 study. The company plans to present Phase 1 clinical trial data at the upcoming 67th American Society of Hematology Annual Meeting.
Cullinan Oncology stock price target raised to $36 at Jones Trading
Jones Trading increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $36, maintaining a Buy rating due to promising data for its CLN-049 treatment for acute myeloid leukemia. This new target implies a significant upside, and the company has multiple therapies advancing, including a New Drug Application for zipalertinib and progress in autoimmune disease treatments. Other analysts, H.C. Wainwright and BTIG, have also raised their price targets on Cullinan Oncology, reinforcing a positive outlook for the company's stock.
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
This article analyzes Cullinan Oncology Inc. (CGEM) using AI models, highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents three institutional trading strategies tailored to different risk profiles—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The analysis also emphasizes elevated downside risk and the absence of clear long-term price positioning signals.
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data
BTIG has raised its price target for Cullinan Oncology (NASDAQ:CGEM) to $38 from $32, maintaining a Buy rating. This upgrade follows promising Phase 1 data for CLN-049 in acute myeloid leukemia (AML), showing a 31% complete response rate and 69% overall response rate at the highest tested dose. The therapy's favorable cytokine release syndrome profile and mutation-agnostic approach suggest significant potential for a broader AML patient population.
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics have initiated a rolling submission for a New Drug Application (NDA) to the FDA for zipalertinib. This oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy. The companies anticipate completing the NDA submission in the first quarter of 2026, building on positive results from the REZILIENT1 trial.
H.C. Wainwright raises Cullinan Oncology stock price target on NDA progress
H.C. Wainwright increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $26.00 from $24.00, maintaining a Buy rating after the company initiated a rolling New Drug Application (NDA) for zipalertinib. The NDA seeks accelerated approval for zipalertinib to treat non-small cell lung cancer with EGFR exon 20 insertion mutations. The submission is supported by positive results from the REZILIENT1 trial, and the firm raised its probability of approval for zipalertinib to 90%.
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data
Taiho Pharmaceutical Co. Ltd. and Cullinan Therapeutics Inc. have initiated a rolling New Drug Application (NDA) with the U.S. FDA for zipalertinib. This application seeks accelerated approval to treat patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor exon 20 insertion mutations, who have previously undergone platinum-based chemotherapy. The NDA submission follows positive phase I/II data for the drug.
(CGEM) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis for Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a positive near-term sentiment that may shift, a lack of clear price positioning, and elevated downside risk. It details three distinct trading strategies (Position Trading, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis to guide investors. The report emphasizes the role of price-sensitive allocations and institutional trading strategies for optimizing risk and returns.
Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D
Cullinan Therapeutics is discontinuing development of two oncology programs, CLN-619 and CLN-617, to streamline its pipeline and extend its cash runway into 2029. This decision reflects the company's strategic pivot towards a hybrid autoimmune and oncology focus, balancing its pipeline and emphasizing T-cell engagers. Cullinan's most advanced asset, zipalertinib for non-small cell lung cancer, is moving towards an FDA submission this year.
Cullinan (NASDAQ: CGEM) announces 69% ORR for CLN-049 in r/r AML; Phase 1 shows manageable safety
Cullinan Therapeutics (NASDAQ: CGEM) announced promising Phase 1 data for CLN-049 in relapsed/refractory AML and MDS, showing significant anti-leukemic activity and a manageable safety profile. The drug achieved a 69% Overall Response Rate (ORR) and 31% Composite Complete Response (CRc) at the highest dose, with responses observed across varying FLT3 mutational statuses, including TP53-mutated AML patients. Cullinan will present updated results at the 67th ASH Annual Meeting in December 2025 and will host an investor event to discuss the findings.
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Cullinan Therapeutics will present new preclinical data for CLN-978, its bispecific T cell engager, at ACR Convergence 2025, demonstrating rapid and deep B cell depletion in both in vitro and in vivo models relevant to multiple autoimmune diseases. The data supports CLN-978's potential to modify the underlying pathophysiology of diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus by robustly depleting target B cells. The company is currently advancing CLN-978's global clinical development through its OUTRACE studies across these three indications.
Cullinan (NASDAQ: CGEM) details CLN-978 data at ACR 2025; deep B cell depletion
Cullinan Therapeutics (NASDAQ: CGEM) will present new preclinical data for CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025 on October 28th. The data shows rapid, dose-dependent B cell depletion in human PBMCs from RA, Sjögren's, and SLE patients, as well as in nonhuman primates after subcutaneous dosing. CLN-978 also reduced circulating B cells, anti-dsDNA IgG, and kidney IgG deposition in an SLE mouse model, supporting its potential as a disease-modifying therapy for various autoimmune diseases.
Understanding the Setup: (CGEM) and Scalable Risk - news.stocktradersdaily.com
This article provides an AI-driven analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis, including support and resistance levels. The analysis also emphasizes the importance of current signals for positioning and risk parameters.
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 11.5% – Here’s Why
Cullinan Therapeutics (NASDAQ:CGEM) saw its stock rise by 11.5% recently. This increase follows several analyst reports setting new price targets, insider stock transactions by Lynx1 Capital Management Lp, and institutional investors adjusting their positions in the company. Cullinan Therapeutics is a biopharmaceutical company focused on developing oncology therapies, with several candidates in various phases of clinical trials.
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Benzinga
Cullinan Therapeutics Inc. and Taiho Oncology Inc. announced new data from the REZILIENT2 study of zipalertinib, showing efficacy in brain metastases for advanced non-small cell lung cancer (NSCLC) patients with specific EGFR mutations. The drug demonstrated an intracranial objective response rate of 31.3% and a disease control rate of 68.8% in measurable CNS disease, with a median intracranial duration of response of 8.1 months. Zipalertinib was well-tolerated, with manageable adverse events, and CGEM stock saw a price increase following the announcement.
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 - BioSpace
Taiho Oncology and Cullinan Therapeutics announced new data on zipalertinib from the CNS involvement cohort of the REZILIENT2 trial in patients with NSCLC with EGFR ex20ins mutations and active brain metastases. The preliminary results showed significant intracranial objective response rates and disease control rates, along with a manageable safety profile. These findings suggest zipalertinib's potential to address a significant unmet medical need for this patient population, warranting further investigation.
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
Taiho Oncology and Cullinan Therapeutics announced new data from the REZILIENT2 study of zipalertinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations or uncommon EGFR mutations and central nervous system (CNS) involvement. The data will be presented at the ESMO Congress 2025, highlighting preliminary efficacy and safety. The study shows promising intracranial objective response rates and disease control rates, suggesting zipalertinib's potential for treating active brain metastases in this patient population.
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
This article compares Black Diamond Therapeutics (BDTX) and Cullinan Therapeutics (CGEM), two biotech companies developing next-generation EGFR inhibitors for cancer treatment, to determine which is the better investment. BDTX, focusing on its lead candidate silevertinib for NSCLC, appears more promising due to its lower valuation, strong fundamentals, and recent positive estimate revisions. CGEM, while having a broader pipeline including zipalertinib, shows declining EPS estimates and has underperformed in price thus far this year.
27.4% Response Rate: Zipalertinib Shows Promise for Hard-to-Treat Lung Cancer with EGFR Mutations
Taiho Oncology and Cullinan Therapeutics presented new data from two clinical trials of zipalertinib at the IASLC 2025 World Conference on Lung Cancer, demonstrating promising response rates and a manageable safety profile in NSCLC patients with EGFR mutations. The REZILIENT1 trial showed a 27.4% confirmed objective response rate in patients with EGFR ex20ins mutations previously treated with amivantamab, while the REZILIENT2 trial reported a 30% confirmed objective response rate in patients with uncommon non-ex20ins EGFR mutations, with a significantly higher response in treatment-naïve individuals. These results highlight zipalertinib's potential as a valuable treatment option for hard-to-treat lung cancer populations.
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Taiho Oncology and Cullinan Therapeutics announced updated efficacy and safety data for zipalertinib at the IASLC 2025 World Conference on Lung Cancer. Data from the REZILIENT1 trial showed a confirmed objective response rate (ORR) of 27.4% in NSCLC patients with EGFR ex20ins mutations previously treated with amivantamab. Preliminary efficacy from the REZILIENT2 trial in patients with uncommon non-ex20ins EGFR mutations demonstrated a confirmed ORR of 30%, highlighting zipalertinib's potential in these challenging patient populations.
Cullinan Oncology stock gets Buy rating from H.C. Wainwright ahead of WCLC data
H.C. Wainwright initiated coverage on Cullinan Oncology Inc. (NASDAQ: CGEM) with a Buy rating and a $24.00 price target, citing upcoming data presentations for zipalertinib at the World Conference on Lung Cancer (WCLC) as a key catalyst. The company appears undervalued with strong financial health and liquidity, nearing regulatory milestones for zipalertinib, which has shown promising Phase 2b trial results for non-small cell lung cancer. Cullinan also recently expanded into autoimmune diseases with the acquisition of velinotamig.
Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer
Cullinan Therapeutics (CGEM) will present updated efficacy and safety data for zipalertinib at the IASLC 2025 World Conference on Lung Cancer. The data comes from the Phase 2b REZILIENT1 trial, which focuses on non-small cell lung cancer patients with EGFR exon 20 insertion mutations previously treated with amivantamab. This presentation highlights the ongoing development of therapies for this specific type of lung cancer.
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Taiho Oncology and Cullinan Therapeutics announced the acceptance of abstracts for zipalertinib at the IASLC 2025 World Conference on Lung Cancer. The presentations will include updated efficacy and safety data from the REZILIENT1 trial for NSCLC patients with EGFR ex20ins previously treated with amivantamab, and preliminary efficacy and safety results from the REZILIENT2 trial for patients with uncommon non-ex20ins EGFR mutations. These findings highlight zipalertinib's potential to address significant unmet needs in NSCLC treatment.
